A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer
NCT ID: NCT03816163
Last Updated: 2025-10-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE2
393 participants
INTERVENTIONAL
2019-03-15
2026-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
There is an unmet medical need to treat people with pancreatic cancer. This study will help find the dose of zolbetuximab to be used with chemotherapy and provide more information on this treatment in adults with metastatic pancreatic cancer. The study is currently ongoing globally. People in this study will be treated with either zolbetuximab and chemotherapy or chemotherapy by itself.
The study's main aims are to find a suitable dose of zolbetuximab to be used with chemotherapy in the second part of this study, to check if zolbetuximab and chemotherapy compared to chemotherapy by itself can improve the survival of people with pancreatic cancer, and to check the safety of zolbetuximab when given with chemotherapy and how well people cope with medical problems during the study.
Adults with metastatic pancreatic cancer can take part. Their cancer is metastatic, has the CLDN18.2 marker in a tumor sample and has not previously been treated with chemotherapy. Metastatic means the cancer has spread to other parts of the body. People cannot take part are if they have recently had radiotherapy and have not recovered, need to take medicines to suppress their immune system, have history of nervous system metastases from their pancreatic cancer, or they have other active cancers that need treatment. People who have a specific heart condition or infections also cannot take part.
This study will be in 2 parts. Part 1 is called the Safety Lead-in Phase. Groups of people will receive 1 of 2 different doses of zolbetuximab: a lower dose or a higher dose, both together with chemotherapy. A medical expert panel will check the results and decide the dose to use in Part 2.
Part 2 is called the Randomization Phase. People will be put in 1 of 2 groups by chance and will be given different treatments either zolbetuximab and chemotherapy or chemotherapy by itself. The chance of receiving zolbetuximab and chemotherapy is twice as high as receiving chemotherapy by itself. In both parts of the study, zolbetuximab and chemotherapy or chemotherapy by itself will be given through a vein. This is called an infusion. Each treatment cycle is 4 weeks (28 days) long and people will have either 2 infusions of zolbetuximab and 3 infusions of chemotherapy or 3 infusions of chemotherapy by itself during each treatment cycle. People will visit the clinic on certain days during their treatment. The study doctors will check for any medical problems from zolbetuximab. Also, people in the study will have a health check including blood tests. On some visits they will also have scans to check for any changes in their cancer. Tumor samples will be taken before treatment if a previous sample is not available. People will have the option of giving a tumor sample after treatment has finished. People will visit the clinic after they stop treatment. They will be asked about any medical problems and will have a health check including blood tests. The number of visits and checks done at each visit will depend on the health of each person and whether they completed their treatment or not.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Zolbetuximab With Chemotherapy in Adults With Pancreatic Cancer
NCT06396091
A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer (PC) Patients
NCT04581343
Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma
NCT01360593
Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
NCT02562898
Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer
NCT04827953
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
zolbetuximab +nab-paclitaxel + gemcitabine
Participants will be treated with zolbetuximab in combination with nab-paclitaxel and gemcitabine for the phase 1 portion of the study to establish the recommended dose of zolbetuximab for the phase 2 portion. In the phase 2 portion, the participants will be treated with zolbetuximab at dose determined by the phase 1 portion of the study in combination with nab-paclitaxel and gemcitabine. Participants will be treated on continuous cycles until they no longer derive clinical benefit in the judgment of the treating physician, have unacceptable toxicity, undergo hematopoietic stem cell transplantation (HSCT), or meet one of the discontinuation criteria; whichever occurs first.
zolbetuximab
Administered as an intravenous infusion.
nab-paclitaxel
Administered as an intravenous infusion
gemcitabine
Administered as an intravenous infusion
nab-paclitaxel + gemcitabine
Participants will be treated with nab-paclitaxel and gemcitabine. Participants will be treated on continuous cycles until they no longer derive clinical benefit in the judgment of the treating physician, have unacceptable toxicity, undergo hematopoietic stem cell transplantation (HSCT), or meet one of the discontinuation criteria; whichever occurs first.
nab-paclitaxel
Administered as an intravenous infusion
gemcitabine
Administered as an intravenous infusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
zolbetuximab
Administered as an intravenous infusion.
nab-paclitaxel
Administered as an intravenous infusion
gemcitabine
Administered as an intravenous infusion
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Not a woman of childbearing potential (WOCBP) OR
* WOCBP who agrees to follow the contraceptive guidance throughout the treatment period and for at least 6 months after the final study drug administration.
* Female subject must agree not to breastfeed starting at screening and throughout the study period, and for 6 months after the final study drug administration.
* Female subject must not donate ova starting at screening and throughout the study period, and for 6 months after the final study drug administration.
* A male subject with female partner(s) of child-bearing potential must agree to use contraception during the treatment period and for at least 6 months after the final study drug administration.
* A male subject must not donate sperm during the treatment period and for at least 6 months after the final study drug administration.
* Male subject with a pregnant or breastfeeding partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy or time partner is breastfeeding throughout the study period and for 6 months after the final study drug administration.
* Subject agrees not to participate in other interventional studies while receiving study drug in present study.
* Subject has histologically or cytologically confirmed adenocarcinoma of pancreas.
* Subjects must have metastatic pancreatic adenocarcinoma that has not been previously treated with chemotherapy.
* Prior treatment with fluorouracil (5-FU) or GEM administered as a radiation sensitizer during and up to 4 weeks after radiation therapy is allowed
* If a subject received adjuvant therapy, tumor recurrence or disease progression must have occurred at least 6 months after completing the last dose of the adjuvant therapy.
* Subjects whose disease progressed on prior treatment with Nab-P and GEM are not eligible.
* Subject has a measurable lesion(s) on at least 1 metastatic site based on RECIST 1.1 within 28 days prior to randomization. For subjects with only 1 measurable lesion and prior radiotherapy, the lesion must be outside the field of prior radiotherapy or must have documented progression following radiation therapy.
* Subject's tumor sample has CLDN18.2 expression in ≥ 75% of tumor cells demonstrating moderate to strong membranous staining as determined by central immunohistochemistry (IHC) testing
* Subject has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
* Subject has predicted life expectancy ≥ 12 weeks.
* Subject must meet all of the following criteria based on the laboratory tests that will be collected within 14 days prior to randomization. In case of multiple laboratory data within this period, the most recent data should be used.
* Hemoglobin ≥ 9 g/dl (no transfusion within 14 days of start of study treatment)
* Absolute neutrophil count ≥ 1.5 x 10\^9/L
* Platelets ≥ 100 x 10\^9/L
* Albumin ≥ 2.5 g/dL
* Total bilirubin ≤ 1.5 x upper limit of normal (ULN)
* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN without liver metastases (≤ 5 x ULN if liver metastases are present)
* Estimated creatinine clearance ≥ 30 mL/min
* Prothrombin time/international normalized ratio (INR) and partial thromboplastin time ≤ 1.5 x ULN (except for subjects receiving anticoagulation therapy)
Exclusion Criteria
* Subject has received radiotherapy for metastatic pancreatic adenocarcinoma ≤ 14 days prior to randomization and has not recovered from any related toxicity.
* Subject has received systemic immunosuppressive therapy, including systemic corticosteroids within 14 days prior to randomization. Subject using a physiologic replacement dose of hydrocortisone or its equivalent (defined as up to 30 mg per day of hydrocortisone or up to 10 mg per day of prednisone), receiving a single dose of systemic corticosteroids or receiving systemic corticosteroids as premedication for radiologic imaging contrast use are allowed.
* Subject has prior severe allergic reaction or intolerance to known ingredients of zolbetuximab or other monoclonal antibody, including humanized or chimeric antibodies.
* Subject has known immediate or delayed hypersensitivity, intolerance or contraindication to any component of study treatment.
* Subject has a known history of a positive test for human immunodeficiency virus infection or known active hepatitis B (positive HBs antigen \[Ag\]) or hepatitis C infection. NOTE: Screening for these infections should be conducted per local requirements.
1. For subjects who are negative for HBs Ag, but hepatitis B core antibody positive, a hepatitis B virus DNA test will be performed and if positive, the subject will be excluded.
2. Subjects with positive hepatitis C serology but negative hepatitis C virus RNA test results are eligible.
3. Subjects treated for hepatitis C with undetectable viral load results are eligible.
* Subject has a history of interstitial pneumonia or pulmonary fibrosis.
* Subject has pleural effusion or ascites ≥ Grade 3.
* Subject has an active autoimmune disease that has required systemic treatment in the past 3 months prior to randomization.
* Subject has active infection requiring systemic therapy that has not completely resolved per investigator judgment within 7 days prior to randomization.
* Subject has significant cardiovascular disease, including:
* Congestive heart failure (defined as New York Heart Association Class III or IV), myocardial infarction, unstable angina, coronary angioplasty, coronary stenting, coronary artery bypass graft, cerebrovascular accident or hypertensive crisis within 6 months prior to randomization;
* History of clinically significant ventricular arrhythmias (i.e., sustained ventricular tachycardia, ventricular fibrillation or Torsades de Pointes);
* QTc interval \> 450 msec for male subjects; QTc interval \> 470 msec for female subjects;
* Cardiac arrhythmias requiring anti-arrhythmic medications (Subjects with rate controlled atrial fibrillation for \> 1 month prior to randomization.)
* Subject has a history of central nervous system metastases and/or carcinomatous meningitis from pancreatic adenocarcinoma.
* Subject has known peripheral sensory neuropathy ≥ Grade 2 unless the absence of deep tendon reflexes is the sole neurological abnormality.
* Subject has had a major surgical procedure ≤ 28 days prior to randomization.
* Subject without complete recovery from a major surgical procedure ≤ 14 days prior to randomization.
* Psychiatric illness or social situations that would preclude study compliance.
* Subject has another malignancy for which treatment is required.
* Subject has any concurrent disease, infection or co-morbid condition that interferes with the ability of the subject to participate in the study, which places the subject at undue risk or complicates the interpretation of data.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Astellas Pharma Global Development, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Astellas Pharma Global Development
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Site ES34022
Córdoba, , Spain
Site ES34005
Lleida, , Spain
Site ES34015
Madrid, , Spain
Site ES34006
Madrid, , Spain
Site ES34009
Madrid, , Spain
Site ES34026
Málaga, , Spain
Site ES34017
Santiago de Compostela, , Spain
Site TW88608
New Taipei City, , Taiwan
Site TW88602
Taichung, , Taiwan
Site TW88601
Taipei, , Taiwan
Site TW88609
Taipei, , Taiwan
Site TR90004
Ankara, , Turkey (Türkiye)
Site TR90006
Ankara, , Turkey (Türkiye)
Site TR90003
Diyarbakır, , Turkey (Türkiye)
Site TR90002
Istanbul, , Turkey (Türkiye)
Site TR90001
Konya, , Turkey (Türkiye)
St. Joseph Heritage Medical Group
Fullerton, California, United States
TOI Clinical research
Whittier, California, United States
Midstate Medical Center
Meriden, Connecticut, United States
Lynn Cancer Institute
Boca Raton, Florida, United States
Baptist Health
Miami, Florida, United States
Cancer Treatment Centers of Atlanta
Newnan, Georgia, United States
University of Illinois at Chicago
Chicago, Illinois, United States
Norton Cancer Institute (NCI)
Louisville, Kentucky, United States
Ochsner Health System
New Orleans, Louisiana, United States
David C Pratt Cancer Center
Creve Coeur, Missouri, United States
Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey, United States
Memorial Sloan Kettering Bergen
Montvale, New Jersey, United States
Roswell Park Cancer Institute
Buffalo, New York, United States
Memorial Sloan Kettering Commack
Commack, New York, United States
Memorial Sloan Kettering Westchester
Harrison, New York, United States
Northwell Health Cancer Institute
Lake Success, New York, United States
Memorial Sloan-Kettering Cancer Center
New York, New York, United States
Memorial Sloan Kettering Nassau
Uniondale, New York, United States
Novant Health Presbyterian Medical Center
Charlotte, North Carolina, United States
Novant Health
Winston-Salem, North Carolina, United States
Houston Methodist Hospital
Houston, Texas, United States
Utah Cancer Specialists
Salt Lake City, Utah, United States
MultiCare Regional Cancer Center - Gig Harbor
Gig Harbor, Washington, United States
Vista Oncology
Olympia, Washington, United States
Virginia Mason
Seattle, Washington, United States
Site AU61008
Gosford, New South Wales, Australia
Site AU61007
Wollongong, New South Wales, Australia
Site AU61005
Fitzroy, Victoria, Australia
Site AU61006
Warrnambool, Victoria, Australia
Site BR55012
Porto Alegre, Rio Grande do Sul, Brazil
Site BR55009
Centro Passo Fundo, , Brazil
Site BR55008
Rio Grande, , Brazil
Site BR55004
Santa Catarina, , Brazil
Site BR55010
São Paulo, , Brazil
Site BR55011
São Paulo, , Brazil
Site CN86001
Beijing, , China
Site CN86008
Beijing, , China
Site CN86014
Beijing, , China
Site CN86026
Changchun, , China
Site CN86009
Chongqing, , China
Site CN86004
Guangdong, , China
Site CN86020
Guangdong, , China
Site CN86016
Guangzhou, , China
Site CN86012
Harbin, , China
Site CN86002
Hubei, , China
Site CN86005
Jiangsu, , China
Site CN86011
Jiangsu, , China
Site CN86025
Jiangsu, , China
Site CN86023
Shandong, , China
Site CN86006
Shanghai, , China
Site CN86013
Shanghai, , China
Site CN86019
Shanghai, , China
Site CN86007
Tianjin, , China
Site CN86022
Xinjiang, , China
Site CN86024
Yanxi, , China
Site CN86003
Zhejiang, , China
Site CN86018
Zhejiang, , China
Site CN86010
Zhengzhou, , China
Site FR33008
Besançon, Besancon Cedex, France
Site FR33010
Brest, Brest Cedex, France
Site FR33015
Caen, Cedex 5, France
Site FR33006
Chambray, Cedex 9, France
Site FR33012
Herblain, Herblain Cedex, France
Site FR33016
La Chaussée-Saint-Victor, Loir-et-Cher, France
Site FR33009
Nancy, Nancy Cedex, France
Site FR33017
Rouen, Normandy, France
Site FR33003
Aquitaine, Pessac, France
Site FR33013
Villejuif, Villejuif Cedex, France
Site FR33001
Bayonne, , France
Site FR33018
Bordeaux, , France
Site FR33002
Grenoble, , France
Site FR33019
La Roche-sur-Yon, , France
Site FR33021
Nice, , France
Site FR33023
Pierre-Bénite, , France
Site FR33014
Plérin, , France
Site FR33005
Pringy, , France
Site FR33007
Strasbourg, , France
Site IR35301
Elm Park, Dublin, Ireland
Site IT39006
Rozzano, Milan, Italy
Site IT39004
Candiolo, Torino, Italy
Site IT39002
Cremona, , Italy
Site IT39010
Lombardia, , Italy
Site IT39003
Milan, , Italy
Site IT39014
Toscana, , Italy
Site IT39008
Veneto, , Italy
Site JP81007
Nagoya, Aichi-ken, Japan
Site JP81001
Kashiwa, Chiba, Japan
Site JP81005
Sapporo, Hokkaido, Japan
Site JP81006
Yokohama, Kanagawa, Japan
Site JP81003
Kashihara, Nara, Japan
Site JP81011
Bunkyo-ku, Tokyo, Japan
Site JP81012
Chuo-ku, Tokyo, Japan
Site JP81014
Koto-ku, Tokyo, Japan
Site JP81013
Mitaka, Tokyo, Japan
Site JP81002
Shinjuku-ku, Tokyo, Japan
Site JP81015
Ube, Yamaguchi, Japan
Site JP81004
Fukuoka, , Japan
Site JP81010
Osaka, , Japan
Site JP81009
Wakayama, , Japan
Site MX52004
Distrito Federal, , Mexico
Site MX52003
San Luis Potosí City, , Mexico
Site MX52005
Veracruz, , Mexico
Site KR82005
Seongnam-si, Gyeonggi-do, South Korea
Site KR82008
Suwon, Gyeonggi-do, South Korea
Site KR82010
Daegu, , South Korea
Site KR82009
Gyeonggi-do, , South Korea
Site KR82001
Seoul, , South Korea
Site KR82003
Seoul, , South Korea
Site KR82004
Seoul, , South Korea
Site KR82007
Seoul, , South Korea
Site KR82002
Seoul, , South Korea
Site KR82006
Seoul, , South Korea
Site ES34004
Llobregat, Barcelona, Spain
Site ES34003
Pamplona, Navarre, Spain
Site ES34010
Barcelona, , Spain
Site ES34013
Barcelona, , Spain
Site ES34007
Barcelona, , Spain
Site ES34018
Barcelona, , Spain
Site ES34021
Barcelona, , Spain
Site ES34014
Cáceres, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018-002551-15
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
CTR20220914
Identifier Type: REGISTRY
Identifier Source: secondary_id
2024-510985-17-00
Identifier Type: REGISTRY
Identifier Source: secondary_id
8951-CL-5201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.